This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.
Name: Ruxolitinib
Description: from the date of transplantation to death from any cause
Measure: Overall survival Time: 3, 6, 12, 24 months after induction chemotherapyDescription: from the date of transplantation to the date of disease progression or death from any cause
Measure: Progression-free survival Time: 3, 6, 12, 24 months after induction chemotherapyDescription: according to CTCAE version 4.03
Measure: Toxicity profile Time: 3, 6, 12, 24 months after induction chemotherapyAllocation: N/A
Single Group Assignment
There is one SNP
JAK2 V617F mutation, which is a hallmark of MPN, has been reported to be carried in approximately 35-50% of patients with post-MPN AML. --- V617F ---